Scribe Therapeutics (SCRE) Investor presentation summary

Mission and vision

• Focused on developing in vivo CRISPR medicines to prevent and treat disease, starting with atherosclerotic cardiovascular disease (ASCVD).

• Aims to shift medicine from late symptom intervention to genetic prevention, extending healthspan and lifespan.

Team and expertise

• Built on Nobel Prize-winning science with a founder-led team and deep industry expertise.

• Headquarters in Alameda, CA, with ~90 employees and strong backing from top-tier investors.

Proprietary technology and approach

• Utilizes CRISPR by Design, with proprietary ELXR (epigenetic silencing) and XE (gene editing) platforms.

• Technologies enable ultra-long-acting gene silencing and editing for safer, more effective genetic medicines.